Biotron Reports $1.52M FY2026 Loss, Completes Sedarex Acquisition

Loss Widens Amid Sedarex Acquisition and R&D Investment

Biotron Limited (ASX:BIT) reported a net loss of $1.52 million for the year ended 30 June 2026, a 376.6% increase from the prior year’s $318,572 loss. The widening deficit reflects costs associated with the December 2025 acquisition of Sedarex Pty Ltd, integration expenses, and ongoing research and development (R&D) activities.

The company’s cash position improved to $1.55 million as at June 30, bolstered by a $2.5 million capital raising comprising a $1 million two-tranche placement and a $1.52 million entitlement offer. Despite this, Biotron’s auditors flagged a material uncertainty over the company’s ability to continue as a going concern, contingent on securing further funding or scaling back expenditure.

Sedarex Acquisition Adds Next-Generation Anaesthetic to Portfolio

The acquisition of Sedarex expanded Biotron’s portfolio beyond antivirals into the neuroscientific and anaesthetic fields. Sedarex holds global patents for SedRxTM, a next-generation general anaesthetic designed to overcome safety issues that led to the withdrawal of the predecessor drug Althesin. SedRxTM aims to offer advantages over propofol, the current standard of care, particularly for vulnerable populations at risk of post-anaesthetic cognitive impairment.

Following shareholder approval in November 2025, Biotron completed the acquisition in December. The transaction saw the issue of 500 million shares valued at $1.5 million plus contingent consideration of 500,000 performance shares worth $500,000, subject to regulatory and clinical milestones. The first milestone was met in July 2026 with European Medicines Agency (EMA) feedback that clarified the regulatory pathway, leading to the conversion of 83.3 million performance shares into ordinary shares.

However, the EMA ruled out a Hybrid Marketing Authorisation Application (MAA) for SedRxTM because the reference product Althesin is no longer marketed, eliminating the possibility of bridging studies. This feedback reduces regulatory uncertainty and allows Biotron to focus on a clinical and regulatory programme aligned with current EMA expectations, including planning pivotal clinical trials to support marketing approval. The company continues to pursue additional neuroscientific indications for SedRxTM, including animal model testing.

Antiviral Pipeline Progresses with Promising HBV and HDV Data

Biotron’s antiviral portfolio remains a core focus, particularly its lead compound BIT-HBV001 targeting Hepatitis B virus (HBV). The compound demonstrated antiviral activity in two animal models and cell-based infectivity studies, outperforming Tenofovir, the current first-line HBV treatment, by inhibiting multiple viral replication endpoints.

In March 2026, Biotron reported BIT-HBV001 also showed activity against Hepatitis Delta Virus (HDV), a satellite virus that co-infects HBV patients and is linked to severe liver disease. This broad antiviral potential addresses a significant unmet medical need, with over 250 million people chronically infected with HBV and up to 60 million with HDV worldwide.

The company has filed patents covering BIT-HBV001 and related compounds, with plans to advance towards human trials, including toxicology and safety studies, and scale-up of production.

Governance Changes and Corporate Developments

Biotron saw notable board changes during the year. Dr Paul Kasian was appointed Non-Executive Director in December 2025 and became Chairman in May 2026 following the retirement of long-term chairman Michael J. Hoy. Michael Medway and Graeme Wald joined as Non-Executive Directors, while Robert Thomas retired in February 2026.

The company received a $525,869 R&D tax incentive rebate for the 2025 financial year. No dividends were declared, consistent with prior years.

Financial and Operational Outlook

Looking ahead, Biotron plans to develop a clinical and regulatory programme for SedRxTM aligned with EMA requirements, including pivotal trial planning. The company will also advance additional neuroscientific indications and progress the HBV program towards clinical trials. Business development efforts to commercialise the portfolio will continue.

The company’s ability to execute these plans hinges on securing additional funding, as highlighted in its going concern note. Biotron’s scientific progress and regulatory clarity for SedRxTM provide a clearer development path, but the timelines and capital requirements inherent to drug development underscore ongoing risk.

Investors should watch for updates on clinical trial milestones, regulatory submissions, and capital raising activities as key indicators of Biotron’s trajectory in the competitive biotechnology sector.